Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
JCO Oncol Pract ; 17(10): 607-614, 2021 10.
Article in English | MEDLINE | ID: covidwho-1060961

ABSTRACT

Despite efforts to enhance enrollment and the merger of national cooperative groups, < 5% of patients with cancer will enroll into a clinical trial. Additionally, clinical trials are affected by a lack of diversity inclusive of minority patients, rural residents, or low-income individuals. COVID-19 further exacerbated known barriers of reduced physician-patient interaction, physician availability, trial activation and enrollment, financial resources, and capacity for conducting research. Based on the cumulative insight of academic and community clinical researchers, we have created a white paper identifying existing challenges in clinical trial conduct and have provided specific recommendations of sustainable modifications to improve efficiency in the activation and conduct of clinical trials with an overarching goal of providing improved access and care to our patients with cancer.


Subject(s)
COVID-19 , Neoplasms , Physicians , Humans , Minority Groups , Neoplasms/therapy , SARS-CoV-2
2.
Cancer Med ; 9(17): 6141-6146, 2020 09.
Article in English | MEDLINE | ID: covidwho-638819

ABSTRACT

The COVID-19 pandemic changed health-care operations around the world and has interrupted standard clinical practices as well as created clinical research challenges for cancer patients. Cancer patients are uniquely susceptible to COVID-19 infection and have some of the worst outcomes. Importantly, cancer therapeutics could potentially render cancer patients more susceptible to demise from COVID-19 yet the poor survival outcome of many cancer diagnoses outweighs this risk. In addition, the pandemic has resulted in risks to health-care workers and research staff driving important change in clinical research operations and procedures. Remote telephone and video visits, remote monitoring, electronic capture of signatures and data, and limiting sample collections have allowed the leadership in our institution to ensure the safety of our staff and patients while continuing critical clinical research operations. Here we discuss some of these unique challenges and our response to change that was necessary to continue cancer clinical research; and, the impacts the pandemic has caused including increases in efficiency for our cancer research office.


Subject(s)
COVID-19 , Clinical Trials as Topic , Neoplasms , Telemedicine , Academic Medical Centers , Ambulatory Care/statistics & numerical data , Health Personnel , Humans , Neoplasms/therapy , Risk Factors , Telemedicine/methods , Telemedicine/statistics & numerical data , Translational Research, Biomedical
SELECTION OF CITATIONS
SEARCH DETAIL